Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
نویسندگان
چکیده
منابع مشابه
Regular insulin, rather than rapid‐acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
The aim of the present study was to compare the usefulness of premeal rapid-acting and regular insulin in type 2 diabetes patients. A total of 56 type 2 diabetic patients were investigated during hospitalization. Premeal rapid-acting insulin was applied instead of other medications. Premeal insulin was titrated to adjust premeal and bedtime blood glucose levels to 81-120 mg/dL. Premeal rapid-ac...
متن کاملFactors Affecting Insulin Compliance in Patients with Type 2 Diabetes in South Iran, 2017: We Are Faced with Insulin Phobia
Background: Many patients with type 2 diabetes are uncontrolled on maximum oral treatment. The early introduction of insulin can lower diabetes-related complications. This study aimed to evaluate type 2 diabetes patients’ demographic characteristics, clinical factors, and attitude toward insulin therapy initiation. Methods: In the present cross-sectional study, 457 patients were selected from 1...
متن کاملShort-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis.
AIM Short-acting insulin analogues, in comparison with regular human insulin (HRI), provide a greater control of postprandial glucose, while their superiority on haemoglobin A1c (HbA1c) is controversial. METHOD All randomized controlled trials (RCTs) with a duration >4 weeks comparing short-acting insulin analogues (lispro, aspart or glulisine) with HRI in type 2 diabetic patients were retrie...
متن کاملPremeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes
OBJECTIVE To assess the effect of three premeal timings of rapid-acting insulin on postprandial glucose excursions in type 1 diabetes. RESEARCH DESIGN AND METHODS Ten subjects participated in a three-way randomized crossover trial. Mean ± SD age was 45.5 ± 12.1 years, A1C was 8.55 ± 1.50%, duration of diabetes was 23.8 ± 7.8 years, and duration of continuous subcutaneous insulin infusion ther...
متن کاملInsulin glargine: a long-acting insulin for diabetes mellitus.
Insulin glargine is a once-daily, biosynthetic, human insulin analogue. Some trials show that in patients with type 1 diabetes mellitus, insulin glargine offers an advantage in blood glucose control compared with NPH insulin. There is some evidence of decreased nocturnal and symptomatic hypoglycemia in patients receiving insulin glargine compared with those receiving NPH insulin, but there are ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes Investigation
سال: 2012
ISSN: 2040-1116
DOI: 10.1111/j.2040-1124.2012.00231.x